Top of the morning to you. And what a morning it is. A lovely sun is shining overhead and a cool breeze is wafting through the Pharmalot corporate campus. This calls for a celebratory cup of stimulation. Nonetheless, meetings and deadlines loom. So let us all get started. A few interesting items can be found below. Meanwhile, if you hear of anything interesting, drop us a line. Have a great day, everyone...
FDA OKs Gilead And J&J Once-Daily HIV Pill (Reuters)
Pfizer Pays First Compensation To Nigerian Trovan Victims (BBC)
Vioxx Lawyers Get More Fees After Filing Objections (Bloomberg News)
Pfizer To Shed 130 Jobs And Close Former King Plant (TriCities)
FDA Sets Review Deadline For Amylin Diabetes Drug (Reuters)
FDA Questions Adventrx Trial Run By CRO In Argentina (Outsourcing Pharma)
Teva Analysts Stick To Buy Ratings No Matter What (Bloomberg News)
EDITOR'S NOTE: Please check this post for updates throughout the morning
1 Comment
First Beacham, then King. Bristol used to be a pharma beehive. Now it's a dead beehive, flattened in the steamrollers known as GSK and Pfizer.